Literature DB >> 10322250

Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group.

P W Connelly1, M Poapst, J Davignon, S Lussier-Cacan, B Reeder, R Lessard, R A Hegele, A Csima.   

Abstract

OBJECTIVE: To determine the population distribution of apolipoproteins A-I and B, and the relationship of apolipoprotein B to lipid risk factors for coronary artery disease.
DESIGN: A stratified random sample of men and women aged 18 to 74 years selected from the provinces of Saskatchewan and Quebec in 1989 and 1990. OUTCOME MEASURES: Plasma concentrations of apolipoproteins A-I and B, triglycerides, low density lipoprotein cholesterol, high density lipoprotein cholesterol and nonhigh density lipoprotein cholesterol for subjects who provided a fasting blood sample. MAIN
RESULTS: Apolipoprotein B mean values increased with age from 0.80 g/L at age 18 to 24 years to a maximum of 1.16 g/L in the 45 to 54 year age group for men. For women, the values increased more gradually from 0.81 g/L for ages 18 to 24 to 1.19 g/L at ages 65 to 74 years. The distribution of apolipoprotein A-I was unrelated to age. Means for men varied from 1.35 g/L to 1.42 g/L and for women from 1.50 g/L to 1.61 g/L. Apolipoprotein B was strongly correlated with nonhigh density lipoprotein cholesterol (r2=0.89), and this was used to define apolipoprotein B concentrations less than 1.04 g/L as indicating low risk for coronary artery disease, from 1.04 g/L to less than 1.22 g/L as moderate risk, from 1.22 g/L to less than 1.40 g/L as high risk, and 1.40 g/L or greater as very high risk. The prevalence of high risk plasma apolipoprotein B levels was higher in men and women with triglycerides greater than 2.3 mmol/L. Apolipoprotein A-I was strongly correlated with high density lipoprotein cholesterol (r2=0.67), and this was use to identify apolipoprotein A-I concentrations of less than 1.20 g/L as a risk factor and 1.65 g/L or greater as an antirisk factor for coronary artery disease. The prevalence of apolipoprotein A-I of less than 1. 20 g/L was 19% in men and 6% in women, whereas the prevalence of apolipoprotein AI 1.65 g/L or greater was 9% in men and 28% in women.
CONCLUSION: Reference values for plasma apolipoproteins A-I and B in a Canadian population random sample are given. Plasma apolipoprotein B and apolipoprotein A-I provide information that is complementary to that provided by low density lipoprotein and high density lipoprotein cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10322250

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  7 in total

1.  Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial.

Authors:  A D Sniderman; J Bergeron; J Frohlich
Journal:  CMAJ       Date:  2001-01-09       Impact factor: 8.262

2.  Prothrombotic markers in asymptomatic dyslipidemic subjects.

Authors:  David Karasek; Helena Vaverkova; Milan Halenka; Dagmar Jackuliakova; Zdenek Frysak; Ludek Slavik; Dalibor Novotny
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

3.  Reference distributions for apolipoproteins AI and B and B/AI ratios: comparison of a large cohort to the world's literature.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Thomas B Ledue; Santica Marcovina; Olga Navolotskaia
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

4.  Effect of the factor VII R353Q missense mutation on plasma apolipoprotein B levels: impact of visceral obesity.

Authors:  Marie-Thérèse Berthier; Alain Houde; Jean Bergeron; Denis Prud'homme; Jean-Pierre Després; Marie-Claude Vohl
Journal:  J Hum Genet       Date:  2003-07-08       Impact factor: 3.172

5.  Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome.

Authors:  Yannick Cyr; Valérie Lamantia; Simon Bissonnette; Melanie Burnette; Aurèle Besse-Patin; Annie Demers; Martin Wabitsch; Michel Chrétien; Gaétan Mayer; Jennifer L Estall; Maya Saleh; May Faraj
Journal:  Physiol Rep       Date:  2021-02

6.  Plasma IL-1Ra: linking hyperapoB to risk factors for type 2 diabetes independent of obesity in humans.

Authors:  S Bissonnette; N Saint-Pierre; V Lamantia; Y Cyr; H Wassef; M Faraj
Journal:  Nutr Diabetes       Date:  2015-09-28       Impact factor: 5.097

7.  Omega-3 polyunsaturated fatty acid profiles and relationship with cardiometabolic risk factors in Cree (Eeyouch) of Northern Québec.

Authors:  Françoise Proust; Olivia Drescher; Elhadji A Laouan-Sidi; Elizabeth Robinson; Michel Lucas; Éric Dewailly
Journal:  Int J Circumpolar Health       Date:  2016-07-15       Impact factor: 1.228

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.